New Appointments at ResverlogixGV, thanks for posting th NR.
The hiring of Mr Paradis and the promotion of Dr. Ewelina Kulikowski to Sr VP of R & D are two very significant events in my opinion.
With 15 years of capital markets and investor relations experience Mr Paradis brings a number of important benefits;
- Substantially improved communications in the investment community. Seems that perhaps Don realized RVX is a the stage where it is now important to get the message out to investors.
- The potential to raise capital.
- Connections and networks.
- Expetise in structuring deals.
- Additional expertise for the next regional deal (or 2).
- Credibility.
- He might even be able to help Don find his reverse takeover target for Zenith that would come with a TSX and/or NASDAQ listing already in place.
I was frustrated at the beginning of but now I sense the momentum is building.
As per BDAZ's post on the other site (Agora) there is a clear need to get control of the messaging because other scientists are implying rvx-208 may, like other BET inhibitors, may have safety issues
but the trials of rvx-208 have proven it is safe at least out to 6 months. It is import that RVX not let competitors control the perceptions of rvx-208 (apabetalone) and in fact clarifying the communications and challenging the scientists who have written the abstracts should boost RVX!
GLTA
Toinv